Reglan Tardive Dyskinesia in Illinois: Tracking Your Medical History

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Education to Targeted Action

If you or a loved one developed tardive dyskinesia after taking Reglan, you may be wondering how to piece together the timeline of exposure and symptoms. Decades of pharmacovigilance have established a clear link between prolonged metoclopramide use and this movement disorder. This page provides a medical record checklist to help you organize key documents for your care team.

Find Out If You Qualify for Compensation →

Understanding Reglan and Its Approved Uses

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved prescribing information includes a boxed warning stating that metoclopramide, including Reglan, can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the label instructs healthcare providers to use the drug for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Tardive Dyskinesia: Symptoms and Mechanism

Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The prescribing information describes TD as a syndrome of potentially irreversible and disfiguring movements that may be suppressed or partially suppressed by metoclopramide, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves dopamine receptor blockade in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent abnormal motor control. This effect is dose-dependent and cumulative, with longer exposure increasing the likelihood of developing persistent symptoms.

Statute of Limitations for Reglan Claims in Illinois

For patients in Illinois considering legal action related to Reglan-induced TD, the statute of limitations is a critical factor. Illinois law generally requires personal injury claims to be filed within two years from the date the injury was discovered or should have been discovered through reasonable diligence. However, the timeline between exposure to Reglan and the onset of TD can complicate this calculation. TD may develop months or even years after starting Reglan, and symptoms can be subtle initially, such as mild tongue protrusion or lip smacking. The prescribing information notes that metoclopramide can suppress or partially suppress signs of TD, which may delay recognition of the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This delay can affect when the statute of limitations begins to run, as the clock typically starts when the plaintiff knows or reasonably should know of both the injury and its cause.

Settlement Considerations and Manufacturer Warnings

Settlement considerations for affected patients often hinge on the adequacy of warnings provided by the manufacturer. The FDA-approved label includes a boxed warning about TD risk, but patients may argue that prescribers and patients were not adequately informed about the potential for irreversible harm, especially with longer-term use. The label states that for patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks, and if longer use is unavoidable, routine monitoring for TD signs is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For gastroesophageal reflux, the maximum duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients were prescribed Reglan for extended periods, sometimes years, without adequate monitoring. The risk of TD is not limited to adults; the label notes that Reglan tablets are not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, off-label use in children has occurred, potentially increasing liability.

Legal Nuances and Next Steps for Illinois Residents

For Illinois residents, the statute of limitations may be tolled (paused) if the patient was under a disability, such as a mental incapacity, at the time of injury. However, TD itself does not typically qualify as a disability for tolling purposes unless it severely impairs cognitive function. The discovery rule is particularly relevant in TD cases because the condition can be misdiagnosed as a psychiatric disorder or other movement disorder, delaying the connection to Reglan. Patients seeking settlements must document the timeline of Reglan use, the onset of TD symptoms, and any medical records showing that the condition was diagnosed. The cumulative dosage and duration of treatment are key factors, as the label explicitly states that risk increases with these variables (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Settlement amounts may vary based on the severity of TD, the degree of disability, and the strength of evidence regarding inadequate warnings. In summary, Illinois patients with Reglan-induced TD face a complex legal landscape. The statute of limitations is generally two years from discovery, but the delayed onset and subtle presentation of TD can extend this window. The FDA label provides clear warnings about TD risk, but long-term use without monitoring remains a common issue. Patients should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances and ensure timely filing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Illinois?

In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. For Reglan-induced tardive dyskinesia, the clock may start later due to delayed onset or subtle symptoms, but it is crucial to consult an attorney promptly.

Can the statute of limitations be extended for Reglan TD cases?

Yes, under the discovery rule, the statute of limitations may begin when the plaintiff knows or should know of the injury and its cause. Additionally, tolling may apply if the patient was under a legal disability, but TD alone typically does not qualify. An attorney can evaluate individual circumstances.

What evidence is needed to support a Reglan TD settlement claim?

Key evidence includes medical records documenting Reglan use (dates, dosage, duration), a confirmed diagnosis of tardive dyskinesia, and records showing the condition was linked to Reglan. Documentation of inadequate warnings or off-label use can also strengthen the claim.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed: Reglan Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.